PHAS

PhaseBio Pharmaceuticals, Inc. Common Stock

Delisted

PHAS was delisted on the 2nd of November, 2022.

51 hedge funds and large institutions have $73.4M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 20 closing their positions.

Holders
51
Holders Change
-10
Holders Change %
-16.39%
% of All Funds
0.79%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
15
Reduced
15
Closed
20
Calls
$275K
Puts
$138K
Net Calls
+$137K
Net Calls Change
+$202K
Name Market Value Shares Shares
Change
Shares
Change %
ACM
51
Altium Capital Management
New York
-775,000 Closed
EP
52
Eversept Partners
New York
-300,000 Closed
CCM
53
CAAS Capital Management
New York
-263,172 Closed
O
54
OrbiMed
New York
-177,113 Closed
Renaissance Technologies
55
Renaissance Technologies
New York
-100,566 Closed
JF
56
Jump Financial
Illinois
-43,867 Closed
BFM
57
Boothbay Fund Management
New York
-40,727 Closed
Jacobs Levy Equity Management
58
Jacobs Levy Equity Management
New Jersey
-31,324 Closed
Goldman Sachs
59
Goldman Sachs
New York
-30,616 Closed
HF
60
HRT Financial
New York
-28,286 Closed
PVI
61
Pura Vida Investments
New York
-27,944 Closed
Squarepoint
62
Squarepoint
New York
-27,083 Closed
CSS
63
Cubist Systematic Strategies
Connecticut
-13,137 Closed
E
64
Ergoteles
New York
-10,881 Closed
TRCT
65
Tower Research Capital (TRC)
New York
$0 110 -8,012 -99%
CAGAS
66
Capital Advisory Group Advisory Services
Minnesota
-2,800 Closed
Group One Trading
67
Group One Trading
Illinois
-1,700 Closed
Federated Hermes
68
Federated Hermes
Pennsylvania
-316 Closed
PHK
69
Point72 Hong Kong
Hong Kong
-164 Closed
OSAM
70
O'Shaughnessy Asset Management
Connecticut
-2 Closed
JPMorgan Chase & Co
71
JPMorgan Chase & Co
New York
$0 17
CFGS
72
Concourse Financial Group Securities
Alabama